Empirical Finance LLC Trims Holdings in Medpace Holdings, Inc. $MEDP

Empirical Finance LLC lowered its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 14.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,782 shares of the company’s stock after selling 1,881 shares during the quarter. Empirical Finance LLC’s holdings in Medpace were worth $5,710,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. California State Teachers Retirement System boosted its stake in Medpace by 53,619.6% during the 2nd quarter. California State Teachers Retirement System now owns 13,989,649 shares of the company’s stock valued at $7,408,778,000 after acquiring an additional 13,963,607 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Medpace in the 2nd quarter worth about $1,323,047,000. AQR Capital Management LLC raised its stake in shares of Medpace by 31.6% in the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after purchasing an additional 324,293 shares in the last quarter. Wasatch Advisors LP lifted its position in shares of Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after purchasing an additional 116,354 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Medpace by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after purchasing an additional 24,625 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Insider Transactions at Medpace

In related news, Director Brian Carley sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the completion of the transaction, the director owned 27,825 shares of the company’s stock, valued at $16,935,129.75. This trade represents a 15.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO August Troendle sold 27,174 shares of the company’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $618.79, for a total transaction of $16,814,999.46. Following the completion of the sale, the chief executive officer directly owned 561,195 shares of the company’s stock, valued at $347,261,854.05. The trade was a 4.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 134,471 shares of company stock valued at $82,151,311 in the last quarter. Company insiders own 20.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on MEDP shares. Barclays set a $600.00 price objective on Medpace in a research note on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. BMO Capital Markets increased their target price on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday, July 24th. Truist Financial lifted their price target on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a report on Friday, July 24th. Finally, Leerink Partners set a $620.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Three analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $595.20.

Medpace Stock Performance

Shares of NASDAQ:MEDP traded down $0.40 during trading hours on Tuesday, hitting $590.89. The stock had a trading volume of 185,216 shares, compared to its average volume of 338,222. The stock’s fifty day simple moving average is $575.80 and its 200 day simple moving average is $501.17. The firm has a market capitalization of $16.49 billion, a price-to-earnings ratio of 34.64, a PEG ratio of 2.64 and a beta of 1.15. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.